Upadacitinib shows rapid improvement in refractory acrodermatitis continua of Hallopeau
Upadacitinib Shows Promise for Treatment of Chronic Skin Condition
This case report and literature review describes a 54-year-old man with a 13-year history of isolated acrodermatitis continua of Hallopeau (…
A new case report shows how a specific medication helped a man with a rare, long-term skin condition and nail inflammation.
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab
Trial shows upadacitinib outperforms adalimumab for rheumatoid arthritis patients
This randomized controlled trial of 492 patients with rheumatoid arthritis and prior TNFi failure found upadacitinib 15 mg daily superior to…
A new trial finds that upadacitinib works better than adalimumab for people with rheumatoid arthritis who did not respond well to previous t…
Upadacitinib 15 mg daily improves pruritus and skin sclerosis in a case of refractory lichen sclerosus
JAK Inhibitor Upadacitinib Shows Promise for Lichen Sclerosus
This case report and brief literature review describes the use of upadacitinib 15 mg daily for a patient with refractory generalized lichen …
A single case report finds upadacitinib may help treat stubborn lichen sclerosus, with no side effects seen over 10 months.
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata
One drug improved skin, hair, and pigment in one man
A 57-year-old man with severe, refractory skin conditions showed significant improvement in dermatitis, vitiligo, and hair loss on upadaciti…
A single patient with three skin conditions saw dramatic improvement after taking upadacitinib for one year.
Meta-analysis of upadacitinib for rheumatoid arthritis finds similar efficacy for 15 mg and 30 mg doses
Upadacitinib improves rheumatoid arthritis symptoms in meta-analysis
This systematic review and meta-analysis of 5,237 participants with rheumatoid arthritis found that upadacitinib 15 mg and 30 mg significant…
A new analysis finds upadacitinib helps rheumatoid arthritis symptoms, but higher dose raises infection risk.
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort
Study compares upadacitinib and other therapies for Crohn's disease remission
This retrospective cohort study of 218 individuals with Crohn's disease found a 94.1% clinical remission rate at 26 weeks for upadacitinib, …
Upadacitinib showed a 94.1% remission rate for Crohn's disease patients at 26 weeks, but this finding comes from a very small group of just …
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months
A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis
Study compares eczema medications, finds upadacitinib 30 mg ranked highest for effectiveness
A network meta-analysis of 16,334 adults with moderate-to-severe atopic dermatitis compared approved systemic targeted therapies.
Upadacitinib 30 mg ranked highest for clearing skin and reducing itch among approved eczema medications in a new analysis of over 16,000 pat…